Alice Epitropoulos MD, FACS.
BLUE BELL, Pa.—Physician Recommended Nutriceuticals (PRN), a leader in physician recommended nutriceutical products for ocular health, announced the appointment of Alice Epitropoulos MD, FACS to the position of chief medical officer. Dr. Epitropoulos will oversee global clinical development and educational initiatives for PRN as they continue to grow past the 5,000 ophthalmologists and optometrists who recommend nutriceutical products to their patients. Key PRN products include De3 Omega Benefits, for patients with occasional eye dryness; Numaqula Vitamin and Numaqula Omega 3, for support of a healthy macula; and Nuretin, for support of retinal health.

Dr. Epitropoulos specializes in refractive cataract surgery and dry eye disease and is a founding member of The Eye Center of Columbus, an innovative affiliation of more than 80 ophthalmologists located in Columbus, Ohio. She will continue to see patients in her private practice. Dr. Epitropoulos also serves as a clinical assistant professor in the Department of Ophthalmology at The Ohio State University. 
She was named one of the top influential female figures in ophthalmology (Power List 2021) and one of Ocular Surgery News’ Premier Surgeon 300, an elite group of 300 premium refractive cataract surgeons in the U.S. Dr Epitropoulos speaks and teaches nationally and internationally on cataract and refractive surgery and innovations in ocular surface disease. She is actively engaged in clinical research and has been published in multiple peer reviewed medical journals, including the article published in Cornea on benefits of taking TGC Omega-3 supplements for dry eye patients.
“We are excited that Alice is bringing her expertise and years of clinical and research experience to PRN. As a strong leader in the ophthalmology community, her presence will prove to be a valuable addition to our clinical team. And we know that her dedication to patient care and excellence will be an ideal fit with our mission to make a fundamental difference in patients’ lives,” said chief executive officer, Ken Krieg.